MEMBERS FUNDING ANNOUNCEMENTS.

The actions funded under this topic should contribute to increased international cooperation among researchers and funders, catalyse research synergies, and leverage resources and investments in order to achieve the reduction of disease burden in SSA through the development of vaccines.

Proposals are expected to include the effective in-kind and/or financial contribution of contributing partners, in order to produce meaningful and significant effects enhancing the impact of the related research activities.

​

This topic aims at supporting activities that contribute to one or several of the expected impacts for this call. To that end, proposals submitted under this topic should aim for delivering results that are directed, tailored towards and contributing to at least two of the following expected outcomes, with the first being mandatory:

• Obtain evidence of immunogenicity, efficacy, safety or clinical utility on vaccine candidates under development and licensed vaccine(s);

• Generate clinical data on TB prophylactic vaccines serving adolescents and adults, and including where appropriate pregnant and lactating women, new-borns, children, other vulnerable and neglected populations, and people with co-infections and co-morbidities at risk in SSA;

• Contribute to the data package related to immunisation/vaccination enabling public health authorities and policy makers to recommend on vaccination strategies, publish updated or new evidence-based clinical guidelines and best practices or design tailor-made TB policies targeting SSA.